Slamon DJ - Search Results

1

A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).

Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. Hurvitz SA, et al. Among authors: slamon dj. Clin Breast Cancer. 2010 Aug 1;10(4):307-12. doi: 10.3816/CBC.2010.n.040. Clin Breast Cancer. 2010. PMID: 20705564 Clinical Trial.

2

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

Press MF, Hung G, Godolphin W, Slamon DJ. Press MF, et al. Among authors: slamon dj. Cancer Res. 1994 May 15;54(10):2771-7. Cancer Res. 1994. PMID: 7909495

3

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. J Clin Oncol. 1998 Aug;16(8):2659-71. doi: 10.1200/JCO.1998.16.8.2659. J Clin Oncol. 1998. PMID: 9704716 Clinical Trial.

4

Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media.

Paquette RL, Gonzales E, Yoshimura R, Tran L, Choi R, Baldwin G, Slamon DJ, Glaspy J. Paquette RL, et al. Among authors: slamon dj. J Hematother. 1998 Dec;7(6):481-91. doi: 10.1089/scd.1.1998.7.481. J Hematother. 1998. PMID: 9919941

5

HER-2/neu as a predictive marker of response to breast cancer therapy.

Pegram MD, Pauletti G, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877. Breast Cancer Res Treat. 1998. PMID: 10066073 Review.

6

Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Pietras RJ, et al. Among authors: slamon dj. Cancer Res. 1999 Mar 15;59(6):1347-55. Cancer Res. 1999. PMID: 10096569

7

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.

Pegram MD, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. Semin Oncol. 1999 Aug;26(4 Suppl 12):89-95. Semin Oncol. 1999. PMID: 10482199 Clinical Trial.

8

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ. Aguilar Z, et al. Among authors: slamon dj. Oncogene. 1999 Oct 28;18(44):6050-62. doi: 10.1038/sj.onc.1202993. Oncogene. 1999. PMID: 10557094

9

Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.

Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM. Strawn LM, et al. Among authors: slamon dj. Clin Cancer Res. 2000 Jul;6(7):2931-40. Clin Cancer Res. 2000. PMID: 10914743

10

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

Pegram MD, Konecny G, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. Cancer Treat Res. 2000;103:57-75. doi: 10.1007/978-1-4757-3147-7_4. Cancer Treat Res. 2000. PMID: 10948442 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters